Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-16-724483
Filing Date
2016-09-29
Accepted
2016-09-29 06:26:03
Documents
3
Group Members
KEN TAKANASHISNBL USA, LTD.

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D AMENDMENT NO. 2 d243396dsc13da.htm SC 13D/A 61128
2 EX-99.6 d243396dex996.htm EX-99.6 14340
3 EX-99.7 d243396dex997.htm EX-99.7 15685
  Complete submission text file 0001193125-16-724483.txt   92964
Mailing Address 8 CROSS STREET #10-00 SINGAPORE U0 048424
Business Address 8 CROSS STREET #10-00 SINGAPORE U0 048424 617-206-4830
Wave Life Sciences Ltd. (Subject) CIK: 0001631574 (see all company filings)

EIN.: 000000000 | State of Incorp.: U0 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89180 | Film No.: 161908251
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2438 MIYANOURA-MACHI KAGOSHIMA CITY KAGOSHIMA M0 891-1394
Business Address 2438 MIYANOURA-MACHI KAGOSHIMA CITY KAGOSHIMA M0 891-1394 81-99-294-2600
Shin Nippon Biomedical Laboratories, Ltd. (Filed by) CIK: 0001657770 (see all company filings)

EIN.: 000000000 | State of Incorp.: M0 | Fiscal Year End: 1231
Type: SC 13D/A